• 1. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 2. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267
• 3. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 4. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 5. Distributed research: a new paradigm for undergraduate research and global problem solving?
  Bruce Parkinson Energy Environ. Sci., 2010,3, 509-511

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives

Introduction to 4-Bromo-1H-pyrazolo[3,4-c]pyridine (CAS No. 1032943-43-3)

4-Bromo-1H-pyrazolo[3,4-c]pyridine, identified by its Chemical Abstracts Service (CAS) number 1032943-43-3, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical and medicinal chemistry. This compound belongs to the pyrazolopyridine class, a scaffold that has been extensively explored for its potential biological activities. The presence of a bromine substituent at the 4-position enhances its utility as a building block in synthetic chemistry, particularly in the development of novel bioactive molecules.

The structural motif of 4-Bromo-1H-pyrazolo[3,4-c]pyridine consists of a fused ring system comprising a pyrazole ring and a pyridine ring. This particular arrangement imparts unique electronic and steric properties, making it a versatile intermediate for constructing more complex pharmacophores. The bromine atom, being an electrophilic center, facilitates further functionalization through cross-coupling reactions such as Suzuki-Miyaura, Stille, and Buchwald-Hartwig couplings. These reactions are pivotal in the synthesis of biaryl compounds, which are prevalent in many drug candidates.

In recent years, 4-Bromo-1H-pyrazolo[3,4-c]pyridine has been employed in the discovery and development of small-molecule inhibitors targeting various therapeutic areas. One notable application lies in the inhibition of kinases, which are enzymes implicated in numerous diseases, including cancer. The pyrazolopyridine scaffold has shown promise in disrupting kinase activity by mimicking ATP binding pockets or interfering with substrate recognition. For instance, derivatives of this compound have been investigated for their potential to inhibit tyrosine kinases, which play a crucial role in signal transduction pathways associated with cell proliferation and survival.

Moreover, the pharmaceutical industry has leveraged 4-Bromo-1H-pyrazolo[3,4-c]pyridine as a precursor in the synthesis of compounds with anti-inflammatory and immunomodulatory properties. Research indicates that certain analogs of this scaffold can modulate inflammatory cytokine production by interacting with specific intracellular signaling cascades. This has opened up avenues for developing novel therapeutics for autoimmune disorders and chronic inflammatory conditions.

The synthetic accessibility of 4-Bromo-1H-pyrazolo[3,4-c]pyridine further underscores its significance in medicinal chemistry. Several synthetic routes have been reported for its preparation, often involving cyclocondensation reactions between appropriate precursors followed by bromination. These methods highlight the compound's role as a key intermediate that can be readily modified to suit specific pharmacological requirements.

Recent advances in computational chemistry have also contributed to the optimization of 4-Bromo-1H-pyrazolo[3,4-c]pyridine derivatives. Molecular docking studies have been instrumental in predicting binding affinities and identifying lead compounds with enhanced potency and selectivity. These computational approaches complement traditional high-throughput screening methods, enabling more efficient drug discovery pipelines.

In addition to its applications in oncology and immunology, 4-Bromo-1H-pyrazolo[3,4-c]pyridine has found utility in the development of antimicrobial agents. The fused heterocyclic system exhibits inherent antimicrobial properties due to its ability to disrupt bacterial cell wall synthesis or interfere with essential metabolic pathways. Researchers have synthesized various derivatives of this compound and evaluated their efficacy against Gram-positive and Gram-negative bacteria. Some promising candidates have demonstrated comparable or superior activity compared to existing antibiotics.

The versatility of 4-Bromo-1H-pyrazolo[3,4-c]pyridine extends beyond its role as an intermediate; it also serves as a platform for exploring structure-activity relationships (SAR). By systematically varying substituents at different positions on the scaffold, chemists can gain insights into how structural modifications influence biological activity. This SAR analysis is crucial for rational drug design and optimizing lead compounds for clinical development.

The future prospects of 4-Bromo-1H-pyrazolo[3,4-c]pyridine are promising, with ongoing research focusing on expanding its therapeutic applications. Emerging fields such as precision medicine and targeted therapy offer new opportunities for leveraging this compound's unique properties. Additionally, advancements in green chemistry principles may lead to more sustainable synthetic routes for producing high-quality batches of this valuable intermediate.

In conclusion, 4-Bromo-1H-pyrazolo[3,4-c]pyridine (CAS No. 1032943-43-3) stands as a cornerstone in modern medicinal chemistry due to its structural versatility and broad range of applications. Its role as a synthetic building block continues to drive innovation across multiple therapeutic domains. As research progresses，this compound will undoubtedly remain at the forefront of drug discovery efforts，contributing to the development of next-generation therapeutics that address unmet medical needs.

• 1357945-76-6(3,4-Dibromo-1H-pyrazolo3,4-cpyridine)
• 1934875-63-4(6-bromo-1H-pyrazolo[4,3-b]pyridine)
• 1032943-41-1(4-Bromo-1-methyl-1H-pyrazolo[3,4-c]pyridine)
• 1382848-65-8(4-Bromo-5-methyl-1H-pyrazolo[3,4-c]pyridine)
• 1256821-58-5(7-Bromo-1H-pyrazolo[4,3-c]pyridine)
• 1234616-30-8(4-Bromo-3-methyl-1H-pyrazolo[3,4-c]pyridine)
• 1150617-54-1(6-Bromo-1H-pyrazolo[4,3-b]pyridine)
• 1256806-33-3(7-Bromo-1H-pyrazolo[4,3-b]pyridine)
• 2177257-61-1(4-bromo-2-methyl-pyrazolo[3,4-c]pyridine)
• 40511-78-2(8-Bromopyrido[3,4-d]pyridazine)